![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
465kB | |
|
PDF (Supplementary Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
241kB |
| Item Type: | Article |
|---|---|
| Title: | Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| Creators Name: | Kroschinsky, F. and Middeke, J.M. and Janz, M. and Lenz, G. and Witzens-Harig, M. and Bouabdallah, R. and La Rosée, P. and Viardot, A. and Salles, G. and Kim, S.J. and Kim, T.M. and Ottmann, O. and Chromik, J. and Quinson, A.M. and von Wangenheim, U. and Burkard, U. and Berk, A. and Schmitz, N. |
| Abstract: | BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a tetraspanin transmembrane protein predominantly expressed on normal and malignant B cells. This phase I, open-label study used a modified 3 + 3 design to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics, and preliminary activity of BI 836826 in patients with relapsed/refractory B cell non-Hodgkin lymphoma (NHL; NCT01403948). Eligible patients received up to three courses comprising an intravenous infusion (starting dose: 1 mg) once weekly for 4 weeks followed by an observation period of 27 (Course 1, 2) or 55 days (Course 3). Patients had to demonstrate clinical benefit before commencing treatment beyond course 2. Forty-eight patients were treated. In the dose escalation phase (1-200 mg) involving 37 Caucasian patients, the MTD was 100 mg. Dose-limiting toxicities occurred in four patients during the MTD evaluation period, and included stomatitis, febrile neutropenia, hypocalcemia, hypokalemia, and hypophosphatemia. The most common adverse events were neutropenia (57%), leukopenia (57%), and thrombocytopenia (41%), and were commonly of grade 3 or 4. Overall, 18 (38%) patients experienced infusion-related reactions, which were mostly grade 1 or 2. Preliminary evidence of anti-tumor activity was seen; three patients responded to treatment, including one complete remission in a Korean patient with diffuse large B cell lymphoma. BI 836826 plasma exposure increased more than proportionally with increasing doses. BI 836826 demonstrated preliminary activity; the most frequent adverse events were hematotoxicity and infusion-related reactions which were manageable after amending the infusion schedule. Although BI 856826 will not undergo further clinical development, these results confirm CD37 as a valid therapeutic target in B cell NHL. |
| Keywords: | BI 836826, CD37, Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Phase I, Relapsed |
| Source: | Investigational New Drugs |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Volume: | 38 |
| Number: | 5 |
| Page Range: | 1472-1482 |
| Date: | October 2020 |
| Additional Information: | Erratum in: Invest New Drugs 39(1): 283–284; Erratum in: Invest New Drugs 39(1): 285–286. |
| Official Publication: | https://doi.org/10.1007/s10637-020-00916-3 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
